Abstracts Archive - Page 2282 of 2425 - ACR Meeting Abstracts

Abstract Number: 2115 • 2012 ACR/ARHP Annual Meeting
Altered Serum Levels of Bone Metabolism Markers in Rheumatoid Arthritis
Lang Jing Zhu¹, Xia Ouyang¹, Lie Dai¹, Dong Hui Zheng¹, Ying Qian Mo¹, Xiu Ning Wei¹, Chan Juan Zou² and Bai Yu Zhang¹, ¹Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ²Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction and disability. Previous studies showed abnormal activation of osteoclasts as well as…
Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting
The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Mehret Birru Talabi¹, Rachel Mackey², Larry W. Moreland³, Jan Dorman⁴, Kevin D. Deane⁵, Jeremy Sokolove⁶, V. Michael Holers⁷, William H. Robinson⁸, Brian Wallitt⁹ and Lewis Kuller¹⁰, ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Washington Hospital Center, Baltimore, MD, ¹⁰Epidemiology, University of Pittsburgh, Pittsburgh, PA
Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…
Abstract Number: 2117 • 2012 ACR/ARHP Annual Meeting
Algorithm Using Genome-Wide SNP Analysis for Prediction of Radiographic Progression Per Year in RA Patients From Multiple Medical Cohorts
Tsukasa Matsubara¹, Satoru Koyano², Yoshitada Sakai³, Keiko Funahashi², James E. Middleton², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Akira Sagawa⁴, Takeo Sakurai⁵, Hiroaki Matsuno⁶, Tomomaro Izumihara⁷ and Eisuke Shono⁸, ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁵Inoue Hospital, Takasaki, Japan, ⁶Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁷Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ⁸Shono Rheumatology Clinic, Fukuoka, Japan
Background/Purpose: Although not yet fully possible, ideally, since patients with rapidly progressing joint destruction need tight initial control, predicting the progression of joint destruction would…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 2119 • 2012 ACR/ARHP Annual Meeting
Interleukin-6 As a Biomarker for the Clinical and Radiological Effectiveness of Methotrexate in Rheumatoid Arthritis
Naoshi Nishina, Hideto Kameda, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is now an anchor drug in the treatment strategy of rheumatoid arthritis (RA) and its effectiveness has been established. However it is…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 2081 • 2012 ACR/ARHP Annual Meeting
Avβ3 Integrin Inhibition with Cilengitide Both Prevents and Treats Collagen Induced Arthritis
Despoina Sykoutri¹, Nisha Geetha², Silvia Hayer³, Peter Mandl¹, Josef S. Smolen⁴, Gerald Prager² and Kurt Redlich³, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Oncology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatologie, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation and osteoclast (OC) mediated bone erosions. AlphaVbeta3 (αvβ3) integrin is highly expressed…
Abstract Number: 2082 • 2012 ACR/ARHP Annual Meeting
Peripheral and Local Effects of Anti-C5aR Treatment in the Collagen Induced Arthritis Model
Christina Andersson¹, Carola Wenander¹, Pernille Usher², Josephine Hebsgaard² and Lars Hornum³, ¹AID Models, Immunopharmacology, Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark, ²Histology, Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark, ³Immunopharmacology, Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark
Background/Purpose: The activated C5a-fragment of complement factor C5 is a potent pro-inflammatory effector molecule that chemo-attracts and activates myeloid cells such as neutrophils, monocytes, and…
Abstract Number: 2083 • 2012 ACR/ARHP Annual Meeting
New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9
Annelie Hellvard¹, Lutz Zeitlmann², Ulrich Heiser³, André Niestroj³, Hans-Ulrich Demuth³, Jan Potempa⁴ and Piotr Mydel¹, ¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ²Ingenium Pharmaceuticals GmbH, Martinsried, Germany, ³Probiodrug AG, Halle/Saale, Germany, ⁴Microbiology Department, Jagiellonian University, Krakow, Poland
Background/Purpose: Cyclin dependent kinase-9 (cdk-9) is transcription regulator of the carboxyterminal domain of RNA polymerase II. The usage of pan-cdk inhibitors such as flavopiridol has…
Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Shunji Yamazaki¹, Masamichi Inami¹, Misato Ito¹, Yasutomo Fujii¹, Kaori Hanaoka¹, Kaoru Yamagami¹, Kenji Okuma¹, Yoshiaki Morita¹, Shohei Shirakami², Takayuki Inoue², Susumu Miyata³ and Yasuyuki Higashi¹, ¹Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ²Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ³Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…
Abstract Number: 2085 • 2012 ACR/ARHP Annual Meeting
T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo
Cornelia M. Spies¹, Edgar Wiebe¹, Jinwen W. Tu², Aiqing Li², Timo Gaber¹, Dörte Huscher¹, Markus J. Seibel², Hong Zhou² and Frank Buttgereit³, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Bone Research Program, ANZAC Research Institute, The University of Sydney, Concord, Australia, ³Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The role of endogenous glucocorticoids (GC) in, and their contribution to the susceptibility and severity of rheumatoid arthritis remains inconclusive. We previously demonstrated that…
Abstract Number: 2086 • 2012 ACR/ARHP Annual Meeting
PI3-Kinase Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells
Stephan Blueml¹, Gernot Schabbauer², Antonia Puchner³, Emine Sahin², Victoria Saferding⁴, Birgit Niederreiter⁵, Josef S. Smolen⁶ and Kurt Redlich⁵, ¹Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, ³Dpt of Rheumatology, Medical University Vienna, Vienna, Austria, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Local bone destruction in rheumatoid arthritis, psoriasisarthritis or ankylosing spondylitis is a serious health burden and the major cause of disability and severely reduced…
Abstract Number: 2087 • 2012 ACR/ARHP Annual Meeting
Regulatory Effect of the Combination of Methotrexate and 1,25-Dihydroxyvitamin D3 On the Balance of Treg and Th17 in Collagen-Induced Arthritis
Jing Luo, Department of Rheumatoloy, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is the physiologically active metabolite of vitamin D, and it may modulate inflammatory response, cell maturation and cell differentiation. More recently,…
Abstract Number: 2088 • 2012 ACR/ARHP Annual Meeting
Annexin A1 Receptor Agonist Suppresses Development of Inflammatory Arthritis
Yuan Hang Yang¹, Yuan Jia², Wenping Kao¹, Wuqi Song³, Zhan-guo Li⁴ and Eric F. Morand¹, ¹Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ²Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ³Harbin Medical University, Harbin, China, ⁴Rheumatology, Peking University People's Hospital, Beijing, China
Background/Purpose: Annexin A1 (AnxA1) is recognized as an endogenous anti-inflammatory molecule. An AnxA1 receptor, formyl-peptide receptor 2 (FPR2), has been identified in human and mice.…
Abstract Number: 2089 • 2012 ACR/ARHP Annual Meeting
High Local Cathepsin Activity in a Murine Rheumatoid Arthritis Model, but Not in an Osteoarthritis Model, Explains the Difference in Cartilage Vdipen Neoepitope Formation
Eline A. Vermeij¹, Marije I. Koenders², Onno J. Arntz³, Miranda B. Bennink¹, Arjen B. Blom⁴, Peter L.E.M. van Lent⁵, Wim B. van den Berg¹ and Fons A.J. van de Loo¹, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and connective tissue destruction. On the other hand, osteoarthritis (OA) is regarded as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].